A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study looks at two medical treatments for people with a disease called multiple myeloma. The first treatment is called Tec-Dara and it will be compared to a second treatment called Daratumumab SC. Both of these treatments will be given to patients along with two other medicines called pomalidomide and dexamethasone or bortezomib and dexamethasone. The goal is to see which treatment works better.
This study looks at two medical treatments for people with a disease called multiple myeloma. The first treatment is called Tec-Dara and it will be compared to a second treatment called Daratumumab SC. Both of these treatments will be given to patients along with two other medicines called pomalidomide and dexamethasone or bortezomib and dexamethasone. The goal is to see which treatment works better.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: